Current projects

We encourage prospective D/P's (donor/participants) to become involved in current and future studies. If a study listed does not apply to your particular situation we still invite you to register so that we may include you in our database and contact you for future studies.

We are looking for D/P's in the following categories:

ID # Required D/P's Enrolled D/P's Remaining D/P's Inclusion Criteria
280242 20 0 20 Prospective Matched Set Collection from HxV Negative Donors (Roche cfDNA tube, K2EDTA plasma and PDB)
280237 5 0 5 Prospective Whole Blood Collection from HxV Negative Donors (Paxgene RNA tubes)
279827 6 40 -34 Pre-Selected HCV RNA Negative Serum Samples from Inventory
279806 2 2 0 Pre-Selected HCV Positive Samples from Inventory with HCV Viral Load
279381 40 40 0 Pre-Selected HxV Negative Serum Samples From Inventory
278992 5 5 0 Pre-Selected SARS-CoV-2 Positive Samples From Inventory
278976 100 102 -2 Prospective Sars-Cov-2 , Flu A, Flu B and RSV Samples Collection_TCZ0006755 / SRF_0002812
277709 30 0 30 Pre-Selected Gonorrhea Positive Samples from Inventory (Urine)
277708 30 4 26 Pre-Selected Chlamydia Positive Samples from Inventory (Urine)
277707 20 20 0 Whole Blood from Healthy Individuals
277324 30 30 0 Pre-Selected RPR Positive Samples from Inventory
277322 30 30 0 Pre-Selected Gonorrhea Positive Samples from Inventory
277321 30 30 0 Pre-Selected Chlamydia Positive Samples from Inventory
277320 30 30 0 Pre-Selected HBsAg Positive Samples from Inventory
277319 30 30 0 Pre-Selected HIV Positive Samples from Inventory
277318 30 30 0 Pre-Selected HCV Positive Samples from Inventory
277194 5 5 0 Pre-Selected Na Citrate plasma HxV Negative Samples From Inventory
277014 10 10 0 High Volume Plasma Collection from HxV Negative Donors - TZC0010364/SRF_0002851
276588 6 6 0 RMS SARS-CoV-2 Samples for Heat Inactivation
276575 500 217 283 Pre-Selected Syphilis Positive / Reactive Samples from Inventory
276035 6 6 0 Pre-Selected HxV Negative Samples From Inventory
276033 200 166 34 Collection protocol for Panel construction (Custom HIV-1 panels, Q_16975)
275984 8 8 0 HIV Positive Stability Study
275841 14 8 6 Pre-Selected Chlamydia Positive Samples from Inventory
275098 55 55 0 Prospective Whole Blood Collection from HxV Negative Female D/Ps
275091 200 187 13 Pre-Selected HBsAg Samples with Viral Load from Inventory
274652 100 115 -15 Prospective SARS-CoV-2 Negative Sample Collection Protocol
274509 200 138 62 Pre-Selected HxV Negative Samples From Inventory
273311 3 3 0 K2EDTA Plasma and PDB from Healthy (HxV Negative) D/Ps - TZC0008969/ SRF_0002832
272798 12 12 0 High Volume Whole Blood Collection from HxV Negative D/Ps - TZC0008853 / SRF_0002839
272790 2 2 0 Pre-Selected Dual Infected Urine Samples from Inventory
272779 20000 1795 18205 Disposition of Negatives Whole Blood samples fron Freezer 48 (talent samples)
272609 5 1 4 HIV-1 Positive Prospective Blood Collection Protocol
- 2 D/Ps with Viral Load over 2,000 cp/mL
- 1 D/P with Viral Load at around 1,000 cp/mL
- 1 D/P with Viral Load at around 2,000 cp/mL
- 1 D/P with Viral Load at around 3,000 cp/mL
272408 2000 91 1909 Disposition of Samples from JRs 140667
272195 24 24 0 Female Vaginal Sample Collection Protocol for Panel Development
272143 400 308 92 Pre-Selected HBV Positive Samples from Inventory with Viral Load and Genotype
271914 100 6 94 COVID-19 Testing; Private Office
271841 25 17 8 Pre-Selected anti-HBs Samples from Inventory
271644 9 8 1 Prospective Whole Blood Collection from HxV Negative D/Ps
271463 800 0 800 Protocol: LIA-CoV-560 - cobas SARS-CoV-2 and cobas SARS-CoV-2 & Influenza A/B Nucleic acid tests for use on the cobas Liat® System: Clinical Performance Evaluation - Las Vegas
271462 800 0 800 Protocol: LIA-CoV-560 - cobas SARS-CoV-2 and cobas SARS-CoV-2 & Influenza A/B Nucleic acid tests for use on the cobas Liat® System: Clinical Performance Evaluation - Northridge
271164 2 1 1 High Volume Whole Blood Units from Healthy Donors (Sodium Citrate) - TZC0007529
270405 6 4 2 Pre-Selected HCV Positive Samples from Inventory with HCV Viral Load
270404 7 2 5 Pre-Selected HBV Positive Samples from Inventory with Viral Load
269024 2 3 -1 Negative Serum samples for HBV Panels_16894
268387 7 2 5 Pre-Selected HIV-1 Positive Samples from Inventory with Viral Load
268012 35 35 0 SARS-CoV-2 Testing (Abbott)
267478 2 0 2 High Volume Whole Blood Units from Healthy Donors - INC5087530
267417 50 46 4 Prescreaning collection for JR 236653 (HIV Positive DPs, Viral Load 1000-8000)
267180 1500 123 1377 Prospective Healthy Subject Blood Collection Protocol
266931 120 17 103 PAS-19SUST053 Testing HBV VL (Abbott & Hologic)
266866 120 25 95 Protocol: FD-001 - Clinical Evaluation of the Fosun COVID-19 Ag Home Test In Symptomatic and Asymptomatic Subjects
266841 2000 412 1588 Disposition of BioRepository Samples from JRs 200854 and 235406_Phase Scientific_Felix Chao
264837 45 45 0 SARS-CoV-2 Testing (Abbott and Hologic)
263501 100 29 71 Protocol: ZPT-001 - Clinical Performance of the Zepto SARS-CoV-2 IgG Self Test In Subjects who are Symptomatic and Asymptomatic from COVID-19 Infection
262723 50 34 16 Pre-Selected HAV Samples from Inventory
262559 27 22 5 Pre-Selected HIV-1 Positive Samples from Inventory with Viral Load, Group and Subtype
262552 200 192 8 Pre-Selected HBsAg Serum Samples from Inventory
261154 800 1877 -1077 Protocol: LIA-CoV-560 - cobas SARS-CoV-2 and cobas SARS-CoV-2 & Influenza A/B Nucleic acid tests for use on the cobas Liat® System: Clinical Performance Evaluation
260890 200 206 -6 K2EDTA Plasma and PDB from Healthy (HxV Negative) D/Ps - TZC0004044/SRF_0002722
260425 2000 4338 -2338 Disposition of BioRepository Samples - Lav/Yellow Tubes
259067 100 50 50 Clinical Evaluation of the Visby Medical Respiratory Health Test for the Detection and Differentiation of SARS-CoV-2, Influenza A and Influenza B Viral RNA - Clinical Protocol TP-000547
256987 15 0 15 Pre-Selected SARS-CoV-2 Positive Nasopharyngeal Swabs from Inventory
254791 1000 15 985 COVID-19 Testing; Private Office
254733 3 4 -1 Negative Serum samples for HBV Panels_16894
253783 9 6 3 Prospective Whole Blood Collection from HxV Negative D/Ps
251350 100 22 78 SARS-CoV-2 Positive Nasal, Oropharyngeal Dry Swab and Raw Saliva Collection Protocol
249722 5 2 3 Fresh Whole Blood from Healthy (HxV Negative) D/Ps with MTS - INC4998359
248874 200 200 0 Normal Serum and Plasma Samples for Panels_Q_16847
245699 20 0 20 Pre-Selected HBV Samples with Viral Loads between 1,000 - 10,000,000 IU/mL
244616 1700 1739 -39 SARS-CoV-2 Hologic Aptima Testing
244149 16 15 1 Normal Serum and Plasma Samples for Panels_Q_16847
243774 60 0 60 Pre-Selected BKV and EBV Negative Plasma Samples from Inventory - SRF_0002565
243767 450 0 450 Pre-Selected BKV and EBV Positive Plasma and Urine Samples from Inventory - SRF_0002565
242730 100 276 -176 Abbott RealTime CT/NG Testing - Protocol 248B1
242729 300 262 38 Vaginal Sample Collection Protocol - Donors with Vaginitis Symptoms
242206 5000 24662 -19662 COVID-19 Testing
241492 500 40 460 Protocol: OQ-COV-PA2 - InteliSwab COVID-19 Rapid Test - 2nd visit
239962 500 41 459 Protocol: OQ-COV-PA2 - InteliSwab COVID-19 Rapid Test
239950 1000 40 960 Protocol: COL-RESP-528 - Collection of Respiratory Swab Samples from Patients with Suspected Respiratory Tract Infections - Miami
239188 500 0 500 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV, HBV, HCV, Syphilis, CMV, Toxo and/or Rubella
237354 1 1 0 Pre-Selected BKV and EBV Positive Plasma Samples from Inventory (Dual Infection)
237350 5 2 3 Pre-Selected BKV Positive Plasma Samples from Inventory
237091 11 0 11 Fresh Whole Blood from Healthy Individuals
236653 5 2 3 HIV-1 Positive Prospective Blood Collection Protocol
- 2 D/Ps with Viral Load over 2,000 cp/mL
- 1 D/P with Viral Load at around 1,000 cp/mL
- 1 D/P with Viral Load at around 2,000 cp/mL
- 1 D/P with Viral Load at around 3,000 cp/mL
235480 19 0 19 Pre-Selected Chlamydia Positive Samples from Inventory (Serum and Plasma)
235406 300 74 226 SARS-CoV-2 RNA Hologic Testing (Felix Chao and Peter Kim)
234803 200 198 2 Collection protocol for Panel construction (Custom HIV-1 Matched sets panels, Q_16976)
234090 17 0 17 Pre-Selected anti-HBs Positive Samples from Inventory
233218 150 8 142 IDS-21MAXCOMBO - SARS-CoV-2 Hologic Aptima Testing
233007 1000 27 973 CBC Initiative, SACQ_0002392 (INC4932295) - SRF_0002617 - Buffy Coat - BCW
231203 100 36 64 Clinical Evaluation of Visby Medical Personal PCR Women’s Sexual Health Test for the Detection of CT, GC and TV using self-collected Vaginal Swabs - Protocol TP-000669
231202 53 53 0 Beta Study of the Visby Sexual Health Test - Clinical Protocol TP-000516
230530 20000 1295 18705 Customer Samples kept in Biorepository (CMVG Samples, Susan Rimpel)
228548 100 102 -2 Remnant VZV Samples (IGG Negative)
228201 20000 466 19534 Customer Samples kept in Biorepository from Minneapolis Medical Research Foundation (MMRF)
227994 130 5 125 PAS-19SUST054 - HCV
227993 130 1 129 PAS-19SUST052 - HBV
227992 130 10 120 PAS-18SUST041 - Evaluation of the BD Vacutainer® K2EDTA Blood Collection Tubes with Hemogard™ Closure using Molecular Diagnostic Testing for HIV-1 Viral Load (VL) Assay
227621 3 2 1 HIV-1 Positive Prospective Blood Collection Protocol:
- Three (3) D/Ps to have an HIV-1 Viral Load of:
Donor #1: 1000 copies/mL (+/- 10%)
Donor #2: 2000 copies/mL (+/- 10%)
Donor #3: 3000 copies/mL (+/- 10%)
226001 100 38 62 SARS-CoV-2 Positive Nasal, Oropharyngeal Dry Swab and Raw Saliva Collection Protocol
225611 10000 0 10000 A Multi Site, Longitudinal, Prospective Collection Protocol in order to obtain Samples from Normal Healthy D/Ps
225101 1000 9 991 COVID-19 Testing; Private Office
224701 360 0 360 cX8-COV-549: Classic Repro Protocol
224514 600 76 524 Initiative to Screen Potential Study Candidates (SUST)
222843 20 0 20 Remnant SARS-CoV-2 Positive Nasopharyngeal Swabs from Inventory
220541 100 42 58 Collection protocol for Panel construction (Custom HIV-1 Matched sets panels, Q_16913)
219607 1000 13 987 COVID-19 Testing; Private Office
219219 22 21 1 Normal Serum and Plasma Samples for Panels_Q_16894, Q_16914 and Q_16913
217882 65 12 53 Prospective SARS-CoV-2 Positive Sample Collection Protocol (NPS and Saliva)
213622 2500 0 2500 Protocol: cX8-CAB-547 - cobas® SARS-CoV-2 & Influenza A/B for Use on the cobas® 6800/8800 Systems: A Method Comparison Study
210071 2500 555 1945 Protocol: cX8-CAB-533 - cobas® SARS-CoV-2 & Influenza A/B for Use on the cobas® 6800/8800 Systems: A Method Comparison Study
208168 1000 111 889 COVID-19 Testing; Private Office
205506 200 0 200 Urine and Saliva Matched Set from Healthy D/Ps
-100 subject collected in the morning until 9 AM
-100 subjects collected in the afternoon after 4 PM
205083 10 0 10 Prospective Urine Collection from Healthy Donors
202732 1000 99 901 PROTOCOL 274C3 - Clinical Evaluation of the Xpert® Xpress CoV-2/Flu/RSV XC Test on the GeneXpert Dx and Infinity Systems in Laboratory and Near-Patient Testing Environment
201758 130 48 82 PAS-18SUST033 - Validation of the Clinical Performance of BD Vacutainer® PPT™ Plasma Preparation Tube with Hemogard™ Closure in Comparison with the Greiner Vacuette® K2EDTA Gel Tubes for Molecular Diagnostic Testing using HIV-1 Viral Load (VL) Assay
200508 1000 60 940 COVID-19 Testing; Private Office
198399 220 0 220 Prospective SARS-CoV-2 Collection from Symptomatic D/Ps
198391 500 0 500 Prospective Healthy Subject Blood Collection Protocol
195801 220 0 220 Prospective SARS-CoV-2 Collection from Symptomatic D/Ps
195775 20000 1380 18620 Customer Samples kept in Biorepository from HBcT2 [JRID#93116]
193266 200 130 70 Prospective SARS-CoV-2 Collection from Symptomatic D/Ps
190737 5000 23 4977 SARS-CoV-2 Survey (PT)
184026 700 542 158 SARS-CoV-2 RNA Hologic Testing
182696 1000 355 645 Protocol: COL-RESP-528 - Collection of Respiratory Swab Samples from Patients with Suspected Respiratory Tract Infections
180141 15 15 0 Normal Serum and Plasma Samples for Panels_Q_16847
178076 130 79 51 PAS -19SUST046 - Evaluation of BD Vacutainer® PPT™ Plasma Preparation Tube with Hemogard™ Closure for Repeatability and Reproducibility of Molecular Diagnostic Testing using HIV-1 Viral Load (VL) Assay
175884 500 97 403 SARS-CoV-2 RNA Hologic Testing
175792 10000 116 9884 COVID-19 Testing; Tu Cara me Sue
175398 10000 552 9448 COVID-19 Testing; Crew-Royal Caribbean Cruises Ltd
175121 1000 27 973 CBC Initiative
174026 1000 122 878 COVID-19 Testing; Private Office
173768 10000 0 10000 A Multi-Site, Multi-Point, Prospective Collection Protocol in order to obtain Saliva, Sputum, Nasal, Pharyngeal, Blood and/or Finger Stick Specimens from SARS-CoV-2 positive subjects
173505 20 20 0 SARS-CoV-2 Positive Nasopharyngeal Swabs from Inventory
172886 1000 1018 -18 COVID-19 Testing; Private Office
169711 400 398 2 SARS-CoV-2, Nasal swab, Nasopharyngeal Swab, Oropharyngeal swab and Saliva
169440 300 110 190 Remnant Pregnancy Samples
169439 100 258 -158 Remnant HSV Samples
168884 50 0 50 Evaluation of the prognostic performance of HostDx ViralSeverity to predict outcomes of SARS-CoV-2
168867 1000 345 655 COVID-19 Testing; Private Office
168264 10 10 0 SARS-CoV-2 Negative Nasal, Nasopharyngeal Swab
168078 50 2 48 Prospective COVID-19 Positive Sample Collection Protocol (NPS and Raw Saliva)
165868 1000 156 844 COVID-19 Testing; Private Office
163904 1000 1000 0 COVID-19 Testing; Private Office
162417 35 34 1 Fresh Whole Blood from Healthy (HxV Negative) D/Ps - SRF_5868_4
161853 100 861 -761 Abbott RealTime CT/NG Testing, Cepheid_248C1& 248C3
157934 1000 803 197 COVID-19 Testing; Private Office
156661 10000 1756 8244 COVID-19 Testing; Private Office
155679 30 313 -283 SARS-CoV-2 Positive Nasal, Oropharyngeal Dry Swab and Raw Saliva Collection Protocol
154904 10000 40 9960 COVID-19 Testing; Private Office
154536 1000 458 542 Cerebral Spinal Fluid (CSF) Unit from Live D/Ps
- Minimum total volume of 500 ml required
- Individual samples of at least 0.25 ml
- The samples must have no trace of hemolysis (red color).
- Stored under -80°C.
- Remnant material acceptable
- No IRB nor Informed Consent needed
- No clinical history
- Custom Manifest file
153900 10000 31302 -21302 COVID-19 Testing, Florida Department of Health
152854 10000 0 10000 A Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from Normal Healthy D/Ps
152825 5000 106640 -101640 COVID-19 Testing
152672 5000 40 4960 Follow-UP_COVID-19 Testing_Blood and Nasopharyngeal Swabs
152645 24 0 24 Female Vaginal Sample Collection Protocol for Panel Development
152331 5000 1654 3346 COVID-19 Testing
151681 5000 3 4997 Refer to Processing Instructions @ Attachment Tab
151476 1 0 1 HIV Group and Subtype Testing
150014 500 64 436 Seegene Validation Collection Protocol from Male and Female Samples
149547 5000 220 4780 Refer to Processing Instructions @ Attachment Tab
TESTS TO SELECT PER LOCATION - REFER TO ATTACHMENT TAB
149267 200 347 -147 Prospective Nasopharyngeal Swab Collection- SRF_5469
148791 5000 32 4968 Refer to Processing Instructions @ Attachment Tab
146391 92 0 92 High Volume Whole Blood Collection to Evaluate The Long-Term Stability of Roche cfDNA tubes - SRF_5743
145574 5000 80 4920 Refer to Processing Instructions @ Attachment Tab
144620 5000 41 4959 Refer to Processing Instructions @ Attachment Tab
144001 100 825 -725 Pediatric EBV Samples (Tested for EBV Early Ag, EBV Nuclear Ag, EBV VCA IgG and EBV IgM):
- 50 samples from subjects with the ages of 2 through 12 years of age AND
- 50 samples from subjects with the ages of 13 through 21 years of age
- Gender: Male or Female
- Minimum Volume: 1.5 mL (1.2 mL's)
- Storage Temperature: Samples must have been frozen at -20°C or below within 2 days of collection.
143401 1500 1158 342 Cerebral Spinal Fluid (CSF) Unit from Live D/Ps
- Minimum total volume of 3000 ml required
- Individual samples of at least 0.25 ml
- The samples must have no trace of hemolysis (red color).
- Stored under -80°C.
- Remnant material acceptable
- No IRB nor Informed Consent needed
- No clinical history
- Custom Manifest file
142755 5000 80 4920 Refer to Processing Instructions @ Attachment Tab
141914 1000 7 993 HIV Initiative
141493 5000 40 4960 HCV Viral Load and Genotype Survey (PT)
141491 5000 18 4982 HBV Viral Load Survey (PT)
141490 5000 40 4960 HIV Viral Load Survey (PT)
140923 5000 80 4920 Refer to Processing Instructions @ Attachment Tab
140922 5000 45 4955 Refer to Processing Instructions @ Attachment Tab
140530 5000 10 4990 Rubella IgG (AAB - PT)
140528 5000 6 4994 ToRCH (AAB - PT)
139409 5000 85 4915 Pregnancy (PT)
137933 5000 0 5000 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV from Cameroon
137683 930 235 695 Preeclampsia Blood Collection Protocol from Asymptomatic and Symptomatic Populations
136025 300 357 -57 EBV Samples (Tested for EBV Early Ag, EBV Nuclear Ag, EBV VCA IgG and EBV IgM)
135041 100 0 100 GC/CT/MG/TV prospective collection at Budapest
134182 100 80 20 HBV/Mayaro Samples from Colombia
133225 200 274 -74 Prospective HCV Positive serum collection
129688 200 123 77 EBV / EBK Samples from National Center of Urology - Tbilisi, Georgia
129538 1000 309 691 RPR Initiative
128402 1000 64 936 CBC Initiative
124266 5000 143 4857 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV from Cote D'Ivoire
122931 5000 1510 3490 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV, HBV, HCV, Syphilis, CMV, Toxo and/or Rubella
122654 5000 171 4829 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV from Swaziland
120851 140 26 114 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HCV
120409 300 84 216 Matched Prospective Collection Protocol from an HCV, HBsAg and/or RPR Positive Reactive Population
109382 100 32 68 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV
109381 300 6 294 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HCV
108692 1000 958 42 HxV Testing Initiative
102772 50 26 24 Random Cadaveric Samples
102419 1000 452 548 Samples on hold for future shipments to China
98830 10000 0 10000 A Multi-Site, Multi-Point, Prospective Collection Protocol in order to obtain PAP, Endocervical Swab, Vaginal Swab, Nasal Swab, Pharyngeal Swab, Rectal Swab, Urethral Swab and/or Urine Samples
98084 1000 562 438 CBC Qualifying Job Request
96278 195 185 10 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV, HBV, HCV, Syphilis, CMV, Toxo and/or Rubella
96055 40 1732 -1692 Hologic Panels for HIV and HCV
94841 500 1 499 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HCV - LGR
93116 700 734 -34 Prospective Blood Collection Protocol from D/Ps with Signs & Symptoms or at High Risk for Hepatitis
80997 5000 428 4572 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV from Cameroon
79734 100 0 100 Prospective Zika Screening and Longitudinal Sample Collection Protocol
78138 300 140 160 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HCV
78137 300 414 -114 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV
74261 10000 0 10000 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV, HBV, HCV, Syphilis, CMV, Toxo and/or Rubella
68258 10000 0 10000 A Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from Normal Healthy D/Ps
66495 200 225 -25 Prospective Blood Collection Protocol in order to Collect Samples from Donor/Participants (D/Ps) in Low Socio-Economic Regions of the World for Dengue
63869 1 2 -1 Negative Material for Panel Member
63868 1000 555 445 Blinded HIV/HBV/HCV Prospective Blood Collection Protocol from Guinea Bissau
56717 20000 0 20000 A Multi-Site, Multi-Point, Prospective Collection Protocol in order to obtain PAP , Endocervical, Vaginal, Nasal and/or Urine Samples
55075 10000 28 9972 Beta HCG Matched Set Prospective Blood Collection Protocol
54664 200 148 52 Random Cadaveric Samples
38626 300 143 157 Prospective Sample Collection of Specifically Diagnosed D/Ps with Diseases of the Liver or Related Complications:
·50 x Alcoholic liver disease
·30 x Autoimmune hepatitis
·30 x Fatty liver disease
·30 x Non-alcoholic Steatohepatitis (NASH)
·30 x Primary Biliary Cirrhosis (PBC)
27615 15000 633 14367 Prospective Blood Collection Protocol in order to Collect Samples from Donor/Participants (D/Ps) in Low Socio-Economic Regions of the World
26761 10000 482 9518 HIV Positive Time Stability Whole Blood Collection Protocol
10694 3000 2234 766 HCV Longitudinal Prospective Blood Collection Protocol
10693 3000 369 2631 HBV Multi-Point Prospective Blood Collection Protocol
8568 300 1649 -1349 Positive Plasma Units from Blood Centers Around the World (HIV, HBsAg & HCV)



BCW helps clinicians during their research process through collection sites and D/P availability. Our collection sites have been duly inspected and adhere to our Good Manufacturing Practices thus ensuring reliability during the collection process. In addition to this we provide training seminars as part of our Quality Assurance in order to maintain the level of quality that our customers are accustomed to.

You will be invited to participate in research studies for the advancement of diagnostic technologies. Participation in these studies is voluntary. Our D/P's are informed of what the research projects are about and are given an Informed Consent, which evidences their willingness to participate. In order to protect our D/P's we never divulge your identity to the research facilities thus guaranteeing D/P confidentiality.



Contact us to learn more